Yahoo Finance

Kiadis Pharma announces U.S. FDA approval to start NK-REALM Phase 2 clinical trial for natural killer (NK) cell therapy produced with PM21

Kiadis Pharma announces U.S. FDA approval to start NK-REALM Phase 2 clinical trial for natural killer (NK) cell therapy produced with PM21 Amsterdam, The Netherlands, May 6, 2020 – Kiadis Pharma N.V. ...
Yahoo Finance

Kiadis announces new data validating and enhancing its PM21 K-NK-cell platform presented today at the ASGCT virtual annual meeting

Amsterdam, The Netherlands, May 12, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that new ...
ascopubs.org

Preclinical assessment of PM21-particle expanded natural killer cells for ovarian cancer treatment.

Targeting the glucose metabolism of monocytic myeloid-derived suppressor cells to stimulate cancer immunity. This is an ASCO Meeting Abstract from the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium ...
Stockhouse

Kiadis announces new data validating and enhancing its PM21 K-NK-cell platform presented today at the ASGCT virtual annual meeting

The first poster presentation (abstract #427) demonstrates similarity between K-NK cells produced with FC21 and PM21 The second poster presentation (abstract #765) shows preclinical data with enhanced ...